share_log

Wedbush Maintains Outperform on Janux Therapeutics, Raises Price Target to $74

Benzinga ·  May 8 22:43

Wedbush analyst Robert Driscoll maintains Janux Therapeutics (NASDAQ:JANX) with a Outperform and raises the price target from $53 to $74.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment